NO991701L - HIV and cancer treatment - Google Patents

HIV and cancer treatment

Info

Publication number
NO991701L
NO991701L NO991701A NO991701A NO991701L NO 991701 L NO991701 L NO 991701L NO 991701 A NO991701 A NO 991701A NO 991701 A NO991701 A NO 991701A NO 991701 L NO991701 L NO 991701L
Authority
NO
Norway
Prior art keywords
hiv
cancer
herbicide
fungicide
virus
Prior art date
Application number
NO991701A
Other languages
Norwegian (no)
Other versions
NO991701D0 (en
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO991701D0 publication Critical patent/NO991701D0/en
Publication of NO991701L publication Critical patent/NO991701L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En metode for å behandle HIV og andre virusinfeksjoner ved administrering av et herbicid eller fungicid eller derivat derav til et dyr eller menneske. Fungicidene eller herbi- cidene kan anvendes sammen med andre behandlinger, f.eks. med AZT- eller protease-inhibitorer for behandling av HIV. Tiabendazol og klorpropam er f.eks. blitt vist til raskt å redusere nivået av virusproduksjon fra cellepopulasjoner som er kronisk infisert med HIV-l og den antivirale effekt opprettholdes med fortsatt forbindelseseksponering. Denne reduksjon av virusproduksjon forekommer ved konsentrasjoner som er ikke-toksiske for vertscellen og som ikke har noen effekt på syntesen av cellulært DNA, RNA og protein. Videre ble kronisk infiserte celler behandlet i forlengede tidsperioder med tiabendazol og klorpropam ikke superinfisert med HIV. En metode for å inhibere vekst av tumorer og cancere i pattedyr som omfatter administrering av et herbicid- eller fungicidderivat er også angitt heri. Fungicidene eller herbicidene kan anvendes sammen med andre behandlinger, f.eks. taxol for behandlingen av bryst-cancer. Forsterkere kan også være inkludert i det herbicide eller fungicide pre- parat. Metoden er særlig effektiv når canceren eller viruset er en animalsk celle som er genetisk modifisert med plante- eller sopp-genetisk material. Et kjemoterapeutisk middel kan også først administreres for å signifikant redusere størrel- sen av canceren og deretter anvendes behandlingen med herbicidet eller_fungicidet. pisse_metpder er særlig effekti- ve når canceren eller viruset er en mutert celle som omfatter plante- eller sopp-genetisk"material.A method of treating HIV and other viral infections by administering a herbicide or fungicide or derivative thereof to an animal or human. The fungicides or herbicides can be used with other treatments, e.g. with AZT or protease inhibitors for the treatment of HIV. Tiabendazole and chloropropam are e.g. has been shown to rapidly reduce the level of virus production from cell populations chronically infected with HIV-1 and the antiviral effect is maintained with continued compound exposure. This reduction in virus production occurs at concentrations that are nontoxic to the host cell and which have no effect on the synthesis of cellular DNA, RNA and protein. Furthermore, chronically infected cells were treated for extended periods of time with thiabendazole and chloropropam not superinfected with HIV. A method for inhibiting the growth of tumors and cancers in mammals comprising administering a herbicide or fungicide derivative is also disclosed herein. The fungicides or herbicides can be used with other treatments, e.g. taxol for the treatment of breast cancer. Amplifiers may also be included in the herbicidal or fungicidal preparation. The method is particularly effective when the cancer or virus is an animal cell genetically modified with plant or fungal genetic material. A chemotherapeutic agent may also be administered first to significantly reduce the size of the cancer and then the treatment with the herbicide or fungicide is used. piss_metpder is particularly effective when the cancer or virus is a mutated cell comprising plant or fungal genetic material.

NO991701A 1997-05-16 1999-04-09 HIV and cancer treatment NO991701L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4672697P 1997-05-16 1997-05-16
PCT/US1997/021564 WO1998051303A1 (en) 1997-05-16 1997-11-26 Hiv and cancer treatment

Publications (2)

Publication Number Publication Date
NO991701D0 NO991701D0 (en) 1999-04-09
NO991701L true NO991701L (en) 2000-01-17

Family

ID=21945046

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991701A NO991701L (en) 1997-05-16 1999-04-09 HIV and cancer treatment

Country Status (19)

Country Link
EP (1) EP0954309A1 (en)
JP (1) JP2000510156A (en)
KR (1) KR20000049064A (en)
CN (1) CN1254281A (en)
AR (1) AR009968A1 (en)
AU (1) AU7402998A (en)
BR (1) BR9712981A (en)
CA (1) CA2268848A1 (en)
CO (1) CO5070657A1 (en)
CZ (1) CZ124999A3 (en)
HU (1) HUP9904092A3 (en)
IL (1) IL129351A0 (en)
NO (1) NO991701L (en)
PE (1) PE11499A1 (en)
PL (1) PL335160A1 (en)
SK (1) SK46999A3 (en)
TR (1) TR199901530T2 (en)
WO (1) WO1998051303A1 (en)
ZA (1) ZA979095B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
JP2002537327A (en) * 1999-02-26 2002-11-05 ナプロ バイオセラピューティクス，インコーポレイテッド Prostate cancer treatment regimen
AU3606700A (en) * 1999-02-26 2000-09-14 Napro Biotherapeutics, Inc. Treatment regimen for hormone-sensitive cancers
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
WO2002015912A1 (en) * 2000-08-25 2002-02-28 Beth Israel Deaconess Medical Center Compounds and methods for inhibiting neuronal cell death
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
AU9279601A (en) * 2000-09-26 2002-04-08 Procter & Gamble Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
AU2002239395A1 (en) * 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles
JP2004115397A (en) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd Liposome comprising therapeutic agent for vascular disease
AU2005313839B2 (en) * 2004-12-06 2010-03-11 Pitney Pharmaceuticals Pty Limited Treatment for cancer
KR101287917B1 (en) * 2004-12-06 2013-07-23 뉴사우스 이노베이션즈 피티와이 리미티드 Treatment for Cancer
US7727967B2 (en) * 2006-02-24 2010-06-01 Boise State University Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
CN101643729B (en) * 2008-08-07 2011-12-28 复旦大学 Nucleic acid molecule NRN1SR22 and application thereof in preparation of anticancer medicaments
WO2015140792A1 (en) * 2014-03-16 2015-09-24 Hadasit Medical Research Services And Development Ltd. Type iii deiodinase inhibitors and uses thereof
CN105418711A (en) * 2015-11-06 2016-03-23 山东大学 Application of alpha-L-rhamnosidase to preparing hydroxycarbamide and glycoside derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2139052C1 (en) * 1993-03-31 1999-10-10 Мерк Энд Ко., Инк. Combination of hiv-protease inhibitor with other antiviral compounds, pharmaceutical composition based on said and method of pharmaceutical composition preparing
US5656615A (en) * 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
SK138397A3 (en) * 1995-04-12 1998-05-06 Procter & Gamble A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancer
US5665713A (en) * 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
PL324904A1 (en) * 1995-08-04 1998-06-22 Procter & Gamble Application of fluconazole in carcinoma development inhibition

Also Published As

Publication number Publication date
TR199901530T2 (en) 1999-10-21
WO1998051303A1 (en) 1998-11-19
NO991701D0 (en) 1999-04-09
IL129351A0 (en) 2000-02-17
CO5070657A1 (en) 2001-08-28
PL335160A1 (en) 2000-04-10
SK46999A3 (en) 2000-05-16
CZ124999A3 (en) 1999-09-15
HUP9904092A2 (en) 2000-04-28
JP2000510156A (en) 2000-08-08
HUP9904092A3 (en) 2000-07-28
PE11499A1 (en) 1999-03-01
CN1254281A (en) 2000-05-24
BR9712981A (en) 2000-04-18
CA2268848A1 (en) 1998-11-19
KR20000049064A (en) 2000-07-25
AU7402998A (en) 1998-12-08
AR009968A1 (en) 2000-05-17
ZA979095B (en) 1998-05-11
EP0954309A1 (en) 1999-11-10

Similar Documents

Publication Publication Date Title
NO991701L (en) HIV and cancer treatment
BR112019023010A2 (en) synergistic mixtures for fungal control in vegetables
ATE142423T1 (en) AQUEOUS DISPERSIONS OF SULFONYL UREA DERIVATIVES
NO974696L (en) Pharmaceutical preparation containing N-chlorophenylcarbamates and N-chlorophenylthiocarbamates for inhibition of virus and cancer growth
Maragos et al. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice
EP3115394A1 (en) Antiviral agent
KR20190032209A (en) Composition For Controlling Plant Viruses and Use Thereof
Hudson et al. The efficacy of amantadine and other antiviral compounds against two salmonid viruses in vitro
JP2004529091A5 (en)
Linas et al. Endothelial cells protect vascular smooth muscle cells from H2O2 attack
EP0068296B1 (en) a new fungicidal composition, processes for its production and its use
US10624892B2 (en) Agent against fungal infections
JP7277476B2 (en) Chemotherapeutic Agents Containing Combinations of Alexidine Dihydrochloride and Sodium Pentaborate Pentahydrate
Keefer Broad-Spectrum Anti-Cancer Activity of O 2-Arylated Diazeniumdiolates
NO20025898L (en) Methods and associated preparations for increasing the survival of aquatic animals and other animals exposed to an aquatic virus, birna virus or other RNA virus
TH43872A (en) HIV and cancer treatment
SU638235A3 (en) Herbicide composition
Purkayastha et al. A phytoalexin type of reaction in the Botrytis infection of leaves of bean (Vicia faba L.)
NO20012540L (en) Use of phosphonomauric acid derivatives for the treatment of infections
EP4064840A1 (en) Method to control septoria tritici resistant to c14-demethylase inhibitor fungicides
Kuznetsova et al. Comparative Action of Salsoline, Salsolidine, and Related Compounds on KML Tissue Culture and Animal Tumor Strains.
Sarao et al. Field efficacy of Cartap hydrochloride (Mortar 75 SG) against stem borers and leaf folder on rice/basmati rice
Ghosh et al. Field evaluation of some new insecticides against brown planthopper Nilaparvata lugens (stål) in rice
Somers The specificity of fungicides
Sontakke et al. Bioefficacy of combination insecticide, buprofezin+ deltamethrin against leaf folder and planthoppers infesting rice

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application